GlassScriptPhysician profile
Taylore Chanillo
NPI 1982352530
$4,488.33
in general payments reported to CMS, 2019-2025
27 companies · $3,011 in 2025
The $3,011 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $59.43 · 2024: $1,418 · 2025: $3,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,425 · Education: $63.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,425.33 |
| Education | $63.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $786.98 | 2024-2025 | |
| Celgene Corporation | $472.53 | 2024-2025 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $432.33 | 2024-2025 | Zeposia |
| Novartis Pharmaceuticals Corporation | $417.45 | 2024-2025 | |
| Biogen, INC. | $334.60 | 2024-2025 | Tysabri |
| Amgen INC. | $324.00 | 2025 | Uplizna |
| Janssen Biotech, INC. | $301.75 | 2024-2025 | Tremfya |
| Genentech, INC. | $246.24 | 2024-2025 | Ocrevus |
| Vanda Pharmaceuticals INC. | $194.56 | 2024-2025 | Ponvory |
| Axsome Therapeutics, INC. | $189.68 | 2025 | Symbravo, Sunosi |
| Genentech USA, INC. | $176.04 | 2024-2025 | Ocrevus, Ocrevus Zunovo |
| Lilly USA, LLC | $103.07 | 2024-2025 | Taltz, Mounjaro, Zepbound |
| Argenx US, INC. | $89.74 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Abbvie INC. | $87.66 | 2023-2025 | |
| Novo Nordisk INC | $75.32 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $52.90 | 2025 | Gamunex-C, Xembify |
| Emd Serono, INC. | $31.46 | 2025 | Mavenclad |
| Genzyme Corporation | $23.82 | 2025 | |
| Ucb, INC. | $18.81 | 2025 | Bimzelx |
| Alexion Pharmaceuticals, INC. | $18.21 | 2024 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $18.20 | 2025 | Acthar |
| Azurity Pharmaceuticals, INC. | $17.20 | 2024 | Horizant |
| Cycle Pharmaceuticals INC | $16.90 | 2025 | Tascenso Odt |
| Astrazeneca Pharmaceuticals LP | $15.23 | 2025 | Farxiga |
| Xeris Pharmaceuticals, INC. | $14.81 | 2025 | Gvoke Hypopen |
| Pfizer INC. | $14.49 | 2025 | |
| Fresenius Kabi USA, LLC | $14.35 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylore Chanillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.